Clinical Trial Update: Study of EC0225 for the Treatment of Refractory or Metastatic Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating EC0225 for refractory or metastatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• EC0225

Snippet

Sponsor: Endocyte | Conditions: Cancer | Phase 1 | Status: COMPLETED